ABSTRACT BACKGROUND The entirely subcutaneous implantable cardioverter-defibrillator (S-ICD) is the first implantable
T he entirely subcutaneous implantable cardioverter defibrillator (S-ICD)
is an alternative to transvenous implantable cardioverter-defibrillators (TV-ICDS)
for the prevention of sudden cardiac death (1) (2) (3) (4) . The first pilot phase human studies of the S-ICD commenced in 2008, followed by subsequent regulatory (1, 2) and post-market studies (3, 4) . Two studies took place to track the initial worldwide experience with and collected the same information as the EFFORTLESS trial. The 6-month to 1-year data for each of these trials were reported separately, with both demonstrating safety and efficacy (2, 3) .
Because of the relatively low rate of adverse events reported in the individual trials, combining these 2 studies provided a unique opportunity to evaluate complications and to collect a significant number of spontaneous events to evaluate the safety and efficacy of the S-ICD system over a longer follow-up period and in a larger group of subjects. The aim of this study is to present the world-wide experience with the S-ICD at a mean of 22-month follow-up by pooling these databases.
METHODS
STUDY COHORT. The study designs and endpoints were similar, enabling this pooled analysis ( Figure 1 ).
The pooled database consisted of 568 patients from the EFFORTLESS registry (3), 308 from the IDE study (2) , and 13 patients from both studies, giving a total of 889 patients who underwent an implantation procedure. Complications were evaluated in all patients who underwent an implantation procedure. Seven patients underwent an implantation procedure, but they were not discharged with a device in the IDE study due to acute ventricular fibrillation (VF) test results, which left an implantation patient cohort of 882. Data were collected until May 21, 2013 for the ongoing EFFORTLESS registry.
Poolability of data across studies was assessed by analysis of incidence of complications, appropriate and inappropriate shocks, conversion efficacy, and mortality. In outcomes that differed by study, exploratory analysis was performed to explain the differences between studies.
Approval for both studies was obtained by local ethics or institutional review boards, and informed consent was obtained from all patients.
Device programming was determined at the discretion of the physician who performed the procedure and was not controlled during the implantation or study durations. The device programming features included 2 possible tachyarrhythmia detection zones: 1) the shock only zone, in which detection and therapy were based on rate only; and 2) an additional conditional zone, in which a morphology analysis algorithm was applied in addition to rate. Each of the zones was described in detail in previous studies (2, 3, 5) .
SAFETY. The complication-free rate methodology was consistent between studies (2,3). The entire pooled cohort was prospectively evaluated for device-related (type I) complications, labeling-related (type II) complications (i.e., events caused by the labeling, including inadequate labeling or situations where the labeling instructions were not followed), and procedure-related (type III) complications that required invasive action to ameliorate the complication. The databases collected these complications over a range of 2 to 1,542 days, including all adverse events, but we focused on mortality, infection, inappropriate shocks and battery longevity, capacitor function, and random hardware or software component failure of the implanted hardware from the day of implantation. EVALUATION OF SPONTANEOUS EVENTS. Spontaneous events were defined as episodes that triggered the device to charge and store an electrogram. This required an episode to be sustained, such that the initial 18 and/or 24 beats of the tachycardia charge criterion was met. For analysis, spontaneous ventricular tachyarrhythmia (VT)/VF episodes (treated and untreated) were subdivided into 2 classes: 1) discrete episodes; or 2) VT/VF storm episodes that included 3 or more treated VT/VF episodes within 24 hours in the same patient (6) . Defining these groups separately prevented the device conversion efficacy rates from being disproportionately affected by a small number of patients who experienced multiple, temporally clustered events.
Rhythm classification of treated and untreated sensed events were reported by the site, and appropriateness of therapy or detection was adjudicated by a sponsor committee (EFFORTLESS) or Clinical Events Committee (IDE). Every spontaneous stored episode was also classified as discrete or as a storm event.
THERAPY CHARACTERISTICS. Evaluation of the time to therapy for spontaneous episodes was defined from the onset of the sustained arrhythmia until a shock was delivered using electrograms produced by interrogation of the S-ICD system. Treatment outcome was defined as successful by type I termination (abrupt) or type II (gradual termination before redetection) conversion. First shock efficacy was defined as conversion of VT/VF arrhythmia before the start of a second charge. Failure to convert was defined as exhaustion of the 5 programmed therapies per event.
STATISTICAL ANALYSIS. Descriptive statistics are reported using mean AE SD, unless otherwise indicated.
Kaplan-Meier analyses were used to estimate the time to first event for mortality, complications, and appropriate and inappropriate shocks. Summary statistics were also used to describe the overall rates for these events and spontaneous conversion efficacy. Study effect, which was defined as the difference in incidence rates that were significantly different between the 2 study databases, was incorporated to adjust for major differences. All statistical analyses were performed using the SAS Enterprise Guide, version 4.3 (SAS 9.3, SAS Institute, Cary, North Carolina).
RESULTS
PATIENT CHARACTERISTICS. The pooled cohort included 889 enrolled patients (detailed characteristics are listed in Table 1 ), 882 of whom had devices and who were followed for a mean of 651 AE 345 days (total patient-years: 1,571.5). The population was generally younger, men, and had more preserved ejection fractions than those previously reported in prospective TV-ICD trials (7) (8) (9) . Primary prevention patients, patients with heart failure, coronary artery disease, atrial fibrillation, and patients with previous TV-ICDs were well represented. The primary prevention patients who had ejection fractions #35 accounted for 43% of the study population, and were excluded.
A summary of the initial S-ICD device programming is provided in Table 2 . The majority of devices were programmed with 2 zones, which provided morphologic discrimination of events with rates in the conditional shock zone. Detection cutoff rates for VF were chosen at the discretion of the operator, and the median of the lowest rate zone was 200 beats/min.
There were no differences in the incidence of appropriate shocks, conversion efficacy, or mortality by study. However, a study effect was noted for a higher rate of inappropriate shocks and complications in the IDE study (early regulatory implantations) compared with the EFFORTLESS trial (post-regulatory commercial implantations).
FREEDOM FROM COMPLICATIONS. The number and type of complications throughout the follow-up period are listed in Table 3 and are illustrated in the Kaplan-Meier curve in the Central Illustration; 4.5% of patients experienced a complication within 30 days Values are mean AE SD (median), range, n (%).
Abbreviations as in Table 1 . There were 115 appropriately detected VT/VF Burke et al.
A included nearly 30% of patients who required secondary prevention among 2,500 patients, but it found a higher 2-year mortality rate of 11% (11). To be fair, the S-ICD experience had younger patients (mean age 50 years) with higher ejection fractions (mean 0.39); therefore, these patients had less advanced heart failure and more functional reserve, which might be factors that explain the lower annual mortality rate.
This was a provocative finding that was not pro- higher cutoff rates and dual zone programming, with significant reductions in inappropriate shocks (10, 23) .
In this pooled analysis, dual zone programming increased from 51% to 95% and was driven by lessons learned from the START study and early implantations in the IDE and EFFORTLESS studies. 
